Your browser doesn't support javascript.
loading
Progressive multifocal leukoencephalopathy in sarcoidosis successfully treated with pembrolizumab.
Öztürk, Gizem; Tekeli, Elif Irem; Erdogan, Seyda; Peker, Elif; Yücesan, Canan.
Affiliation
  • Öztürk G; Department of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye. ozturkgizem96@gmail.com.
  • Tekeli EI; Department of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye.
  • Erdogan S; Department of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye.
  • Peker E; Department of Radiology, Ankara University School of Medicine, Ibni Sina Hospital, Ankara, 06230, Türkiye.
  • Yücesan C; Department of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye.
J Neurovirol ; 2024 Aug 18.
Article in En | MEDLINE | ID: mdl-39155352
ABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a severe, demyelinating disease of the central nervous system caused by JC virus infection. The disease can be seen in sarcoidosis patients without additional risk factors. Here, we present an individual with PML secondary to sarcoidosis treated with 8 doses of pembrolizumab, a Programmed Cell-Death-1 (PD-1) Immune Checkpoint Inhibitor who showed significant improvement. This report illustrates the objective clinical and radiological improvement in a patient with PML due to sarcoidosis, and suggests further study of immune checkpoint inhibitors as a potential treatment for sarcoidosis patients with PML.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Neurovirol Journal subject: NEUROLOGIA / VIROLOGIA Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Neurovirol Journal subject: NEUROLOGIA / VIROLOGIA Year: 2024 Type: Article